Interferon-α-2b plus ribavirin: A review of its use in the management of chronic hepatitis C

Drugs

Volumn 62, Issue 3, 2002, Pages 507-556

  Scott, Lesley J ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Chronic hepatitis C; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; DIDANOSINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; REBETRON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRANSFORMING GROWTH FACTOR BETA1; VIRUS RNA;

ANOREXIA; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLAMMATION; INFLUENZA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MENTAL DISEASE; NONHUMAN; PRACTICE GUIDELINE; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME; VIRUS LOAD;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036190222     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262030-00009     Document Type: Review

References (232)

1. Epidemiology of hepatitis C
2. Recurrent hepatitis C after liver transplantation
3. Diagnosis and management of chronic hepatitis C
4. Treatment strategies for chronic hepatitis C virus infection
5. National Institutes of Health Consensus Development Conference panel statement: Management of hepatitis C
6. Hepatitis C: The clinical spectrum of disease
7. Advances in the treatment of hepatitis C
8. Pharmacological management of chronic viral hepatitis
9. Hepatitis C virus infection: Pathogenesis, diagnosis and treatment
10. Management of chronic hepatitis C in HIV-infected patients
11. The hepatitis C virus: Overview
12. The cellular tropism of HCV
13. Hepatitis C and liver transplantation
14. Therapy of hepatitis C: Patients with cirrhosis
15. Hepatitis C: Controversies, strategies and challenges
16. French consensus conference on hepatitis C: Screening and treatment
17. A French consensus conference on hepatitis C: Screening and treatment
18. Hepatitis C virus recurrence after liver transplantation
19. Clinical outcomes after transfusion-associated hepatitis C
20. Pathophysiology and treatment of hepatitis C
21. Chronic viral hepatitis C: Management update
22. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
23. A propose system for the nomenclature of hepatitis C viral genotypes
24. Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin of disease
25. Pathophysiology and treatment of hepatitis C infection
26. Interferon-α in malignant and viral diseases
27. National Institutes of Health Consensus Development Conference panel statement: Management of hepatitis C
28. Side effects of alpha interferon in chronic hepatitis C
29. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference
30. Clinical guidelines on the management of hepatitis C
31. Molecular mechanisms of action of ribavirin
32. Major therapeutic uses of interferons
33. Biological basis for the clinical use of interferon
34. Interferon-induced proteins and the antiviral state
35. Mechanisms of the antiviral action of interferons
36. 2′,5′-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C
37. Type 1 interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells
38. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
39. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
40. Ribavirin treatment for chronic hepatitis C
41. A pilot study of ribavirin therapy for chronic hepatitis C
42. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C
43. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
44. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
45. Intestinal absorption of ribavirin is preferentially mediated by the Na+ nucleoside purine (N1) transporter
46. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters
47. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase
48. Ribavirin: An antiviral agent
49. The clinical pharmacology of ribavirin
50. Broad-spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
51. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture
52. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent
53. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover
54. Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
55. Effects of the ribavirin-interferon alpha combination on cultured blood mononuclear cells from chronic hepatitis C patients
56. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine
57. Natural killer cell activity in hepatocellular carcinoma: In vitro and in vivo responses to interferon
58. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and post-treatment with interferon alfa
59. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b
60. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
61. Mechanism of action of ribavirin in treatment of recurrent hepatitis C after liver transplant
62. Study of the effects of ribavirin on cytokine production of recall antigen and PHA-stimulated peripheral mononuclear cells
63. Ribavirin treatment of recurrent hepatitis C virus following liver transplantation: Proposed mechanism of action
64. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
65. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile
66. Effects of INF-α-therapy compared to combined therapy with ribavifin/INF-α on cytokine profiles, natural killer cell activity and costimulatory molecule expression in patients with chronic hepatitis C
67. Treatment of hepatitis C infection +/- ribavirin promoted conversion of TH2 to TH1 cytokine profile and decreased inflammation
68. Influence of IFN and ribavirin on ICAM-1 serum concentration in chronic C hepatitis treatment
69. Interferon-α-2a: A review of its use in chronic hepatitis C
70. Interferon-α-nl: A review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis
71. Neutralizing antibodies to interferon-α: Relative frequency in patients treated with different interferon preparations
72. The differential effects of three forms of interferon alfa on hepatic regeneration after partial hepatectomy in the rat
73. The effect of interferon-alfa-2B/ribavirin (Rebetron) on serum transforming growth factor beta-1 in patients with chronic hepatitis C
74. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes
75. Inhibition of lymphocyte proliferative responses by ribavirin
76. Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities
77. Current perspectives on the treatment and prevention of hepatitis C infection
78. Therapy of hepatitis C: An overview
79. The interferons: Mechanisms of action and clinical applications
80. Inhibition of hepatitis B virus in tissue culture by alpha interferon
81. Hepatitis C virus resistance to antiviral therapy
82. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
83. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus lb: Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region
84. Early changes in HCV hypervariable region 1 (HVR1) and non structural (NS) 5A gene quasispecies during interferon-α or ribavirin treatment: Clues to the mechanisms of HCV resistance to anti-viral therapy
85. Evidence for reduced rates of quasispecies diversification during combination interferon plus ribavirin therapy for chronic hepatitis C
86. The acquired immune response
87. Acute hepatitis C
88. Future approaches to treatment of chronic hepatitis B and hepatitis C infection
89. Hepatitis C virus-specific T lymphocyte responses
90. Cellular and humoral immune reactions against autoantigens and hepatitis C viral antigens in chronic hepatitis C
91. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
92. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
93. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
94. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
95. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
96. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
97. Detection of type-2-like T-helper cells in acute hepatitis C virus infection: Implications for hepatitis C virus chronicity
98. HLA class 1I genes in chronic hepatitis C virus: Infection and associated immunological disorders
99. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in northern European caucasoids
100. Role of specific T-cell response for clearance and control of hepatitis C virus
101. Vigorous peripheral blood cytotoxic T cell responses during the acute phase of hepatitis C virus infection
102. Immunity to hepatitis C virus: A further piece of the puzzle
103. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia
104. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
105. Differential effect of alpha-interferons on CD4- and CD8-positive lymphocytes in chronic hepatitis B virus carriers
106. Ribavirin decreases interferon-gamma production in liver transplant recipients with recurrent HCV infection
107. Transforming growth factors β1 and alpha in chronic liver disease
108. Transforming growth factor beta
109. Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: Association with regression of hepatic fibrosis
110. Hepatic expression of mature transforming growth factor-β 1 in transgenic mice results in multiple tissue lesions
111. Alpha-interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers
112. Interferon-α-2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection
113. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection
114. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN
115. 2 neutralizing antibodies in hepatitis patients
116. Paricalcitol injection and ribavirin/interferon alfa-2b
117. Safety, efficacy and pharmacokinetics of interferon-alfa-2b and ribavirin in children with chronic hepatitis C
118. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology
119. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease
120. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV
121. Ribavirin
122. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro
123. A phase-1 study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients in HIV-1 disease
124. Evaluation of long-term efficacy of interferon α-2b and ribavirin in combination in naive patients with chronic hepatitis C: An Italian multicenter experience
125. Interferon induction therapy in combination with ribavirin in chronic hepatitis C
126. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
127. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C
128. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
129. Interferon α-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
130. Retreatment for chronic hepatitis C of interferon non-responder patients. Preliminary results of a multicenter, randomised, controlled trial of interferon plus ribavirin versus interferon alone
131. A randomized trial of daily interferon α-2b in combination with ribavirin vs three times a week for one month, followed by three times a week for one year in relapse and nonresponder patients
132. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
133. Clinical resolution of hepatitis C in the era of interferon-α/ribavirin combination therapy - Data on interferon-α relapsers at the end of 6-month follow-up
134. Efficacy of interferon and ribavirin for hepatitis C in patients previously treated with interferon alone
135. A randomized 40 arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone
136. Treatment of severe hepatitis C: Interferon + ribavirin vs interferon
137. IFN-α and ribavirin combination therapy reduces the occurrence of breakthrough in chronic hepatitis C
138. Interferon/ribavirin combination therapy with and without daily dosing in retreatment of chronic hepatitis C
139. Rapid viral clearance with IFN-α 2b induction therapy and ribavirin for chronic HCV infection
140. Intron A + ribavirin induction therapy for treatment of community patients with chronic hepatitis C not previously treated with interferon
141. Retreatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination (INF-RIBA) therapy
142. Multicenter, placebo-controlled, double-blind trial of interferon α-2B plus ribavirin vs. interferon alone for retreatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon: A 48 week review
143. The efficacy of combined interferon-alfa-2B and ribavirin therapy in patients with chronic hepatitis C: Final reports of a multicenter study with 100 patients in Hungary
144. Combined interferon and ribavirin therapy in patients with chronic hepatitis C. Preliminary results of a prospective multicenter study
145. Effect of initial interferon dosing and dose on early response to combination therapy with ribavirin in chronic hepatitis C
146. Interferon (IFN) and ribavirin (RVN) for treatment (TX) of chronic HCV in IFN non-responders (NRs)
147. Retreatment with IFN alfa 2B + ribavirin (24 vs 48 weeks) for patients with chronic hepatitis C who relapsed or did not respond to IFN alone
148. Alfa-interferon with ribavirin for the treatment of chronic hepatitis C in treatment naive patients
149. Does race predict outcome in intron-A plus ribavirin (rebetron) for the treatment of chronic hepatitis C in prior interferon monotherapy non-responders? Results of the Washington, DC Metropolitan Area Hepatitis C Investigators Study
150. Intron A plus ribavirin for the treatment of chronic hepatitis C in prior interferon monotherapy non-responders and relapsers: Results of the Washington, DC Metropolitan Area Hepatitis C Investigators Study
151. Intron-A plus ribavirin (Rebetron) for the treatment of chronic hepatitis C in prior interferon monotherapy non-responders (NRS): Final results of the Washington, DC Metropolitan Area Hepatitis C Investigators Study
152. Efficacy, safety and tolerability of daily, high dose interferon α-2B with or without ribavirin for retreatment of HCV infected patients who did not respond to initial interferon monotherapy: An interim report of the AusHep 6 study
153. Retreatment of IFN nonresponders or relapsers with chronic hepatitis C with high dose interferon in combination with ribavirin
154. Antiviral efficacy and safety of ribavirin with daily versus TIW interferon A-2B for chronic HCV infection
155. Interferon alfa plus ribavirin in chronic hepatitis C relapsers and non-responders to previous interferon alfa course
156. Double-blind, placebo-controlled trial of interferon α-2b plus ribavirin versus interferon α-2b for retreatment of patients with chronic hepatitis C who failed previous treatment with interferon alpha
157. Interferon-α (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C (CHC): Interim analysis of an ongoing study (SASL 10)
158. Retreatment with interferon-ribavirin according to viremia of interferon responder-relapser patients: French multicenter randomized controlled study
159. Virologic response in re-treatment of chronic responders (NR) and responder-relapsers (RR): INF induction followed by combination ribavirin vs combination ribavirin: High dose IFN (780 MIU/52 weeks)
160. Preliminary analysis of a multicenter trial of ribavirin plus interferon α-2b previous predictors of response invalidated
161. End of therapy response in naive pts: 6MU IFN α-2B + ribavirin vs IFN α-2B 6MU alone
162. Interferon alfa-2B and ribavirin in patients with resistant chronic hepatitis C
163. Ribavirin/interferon α-2b (IFN) therapy is very effective in the treatment of chronic hepatitis C genotype 2 and 3 patients who have failed to respond virologically to IFN monotherapy
164. Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (RR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks Rebetron therapy)
165. Induction interferon α-2b 5MU daily for 4 weeks followed by combination interferon-ribavirin versus interferon-ribavirin without induction therapy for previously untreated chronic hepatitis C
166. Continuous combination therapy has superior viral clearance compared to standard combination therapy: A multicenter, randomised trial
167. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
168. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy
169. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
170. Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-α in interferon nonresponders with chronic hepatitis C
171. Intravenous recombinant interferon-beta versus interferon-α-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-α
172. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone
173. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy
174. Efficacy of 5MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: A randomized controlled trial
175. Interferon-α and ribavirin treatment of hepatitis C in children with malignancy in remission
176. Making end points meet
177. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection
178. Evaluation of hepatic HCV RNA before and after treatment with interferon alfa 2b or combined with ribavirin in chronic hepatitis
179. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
180. An algorithm for the grading of activity in chronic hepatitis C
181. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
182. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
183. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination
184. Combination of interferon-α and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation
185. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
186. Chronic hepatitis C in HIV-coinfected patients: Feasibility and efficacy of interferon-a-2b and ribavirin combination therapy
187. Antiviral therapy of hepatitis C
188. Factors predictive of a beneficial response to therapy of hepatitis C
189. Racial differences in responses to therapy with interferon in chronic hepatitis C
190. Hepatitis C virus six years on
191. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C
192. The impact of interferon plus ribavirin on response to therapy in Black patients with chronic hepatitis C
193. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
194. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C
195. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response
196. The effects of interferon alfa-2b in combination with ribavirin on health related quality of life and work productivity
197. Therapy of hepatitis C: Cost-effectiveness analysis
198. Cost-effectiveness of treatment for chronic hepatitis C
199. Cost-effectiveness of combined interferon and ribavirin versus interferon alone
200. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C
201. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
202. Cost effectiveness of interferon α-2b combined with ribavirin for the treatment of chronic hepatitis C
203. Estimates of the cost-effectiveness of a single course of interferon-α 2b in patients with histologically mild chronic hepatitis C
204. Pretreatment evaluation of chronic hepatitis C: Risks, benefits and costs
205. The long-term pathological evolution of chronic hepatitis C
206. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
207. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C
208. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
209. Hepatocellular carcinoma in Italian patients with cirrhosis
210. Interferon α-2b and ribavirin vs interferon α-2b and amantadine for chronic hepatitis C (non-responder): A multi-center, randomized, double-blind trial
211. Combination treatment with interferon-α-2b and ribavirin for chronic hepatitis C in patients who failed to show a sustained response to interferon alone: Swedish experience
212. Interferon-α-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis
213. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
214. Safety of combination interferon alfa-2b/fibavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
215. Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment
216. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy
217. Autoimmunity induced by interferon-α therapy for chronic viral hepatitis
218. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy
219. Diabetic ketoacidosis induced by interferon alfa and ribavirin in the patient with hepatitis C
220. Therapy of hepatitis C: Other options
221. Future directions in the treatment of patients with chronic hepatitis C virus infection
222. Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?
223. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
224. A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
225. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
226. Combination therapy with interferon-α and ribavirin for hepatitis C: Practical treatment issues
227. Canadian Consensus Conference on the management of viral hepatitis
228. EASL International Consensus Conference on hepatitis C